Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-tubulin in helminths is a key structural protein forming heterodimers with alpha-tubulin to assemble microtubules, essential cytoskeletal components involved in cell division, intracellular transport, and maintaining cell structure. In parasitic helminths (such as nematodes and cestodes), beta-tubulin is the primary molecular target of the benzimidazole class of broad-spectrum anthelmintic drugs, including albendazole and mebendazole. These compounds bind specifically to β-tubulin, inhibiting microtubule polymerization and function, which is lethal to the parasites. Resistance to benzimidazoles is a major concern in helminth control programs and is often caused by point mutations at specific residues (F167, E198, F200) in the β-tubulin gene, which reduce drug binding affinity. Helminths may express multiple β-tubulin isotypes, some of which are preferentially targeted by drugs or contribute more significantly to resistance. As a well-validated and widely leveraged therapeutic target in veterinary and human medicine, understanding β-tubulin’s structure, function, and variability is critical for ongoing surveillance of resistance and the development of new antiparasitic strategies.
Benzimidazoles and related drugs bind to β-tubulin, inhibiting microtubule polymerization. This disrupts essential processes like cell division, intracellular transport, and formation of structural organelles, ultimately leading to parasite death. Mutations at key amino acid residues (e.g., F167Y, E198A, F200Y) in β-tubulin decrease binding affinity of these drugs, conferring drug resistance.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-tubulin in helminths (β-tubulin (in helminths)).